GGPS1 and chronic myelogenous leukemia, BCR-ABL1 positive: To gain further insight on the pharmacodynamics associated with GGPPS inhibition in the AML mouse model, at end of the study (day 38), spleens and bone marrows (BM) were harvested from animals in the control group and the CML-07–119-treated group, 16 hours following a single dose administration of either PBS or 3 mg/kg of GGPPS inhibitor, respectively.